We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be attending the American Intellectual Property Law Association (AIPLA) 2026 Spring Meeting. She will also be participating as a speaker at the AIPLA Chemical Patent Practice Institute, presenting on the China perspective at an international panel on written description. The Chemical Patent Practice Institute will take place from May 11 to 12, while the Spring Meeting will take place from May 13 to 15, 2026, at the historic Fairmont San Francisco.

As one of the most significant gatherings for intellectual property professionals in North America, the AIPLA Spring Meeting is a hub for high-level discussion on the legislative and judicial trends shaping the future of IP. This year's program highlights the intersection of innovation and technology, with a deep focus on "The Future of IP in an AI-Driven World."

If you or your firm will be in San Francisco for AIPLA2026, Jennifer would be delighted to meet to discuss cross-border patent strategies or our specialized services in China. Please reach out to us to schedule a meeting during the conference.

我們過去活動

Recommended Insights

A More Detailed Overview of China’s Patent Term Extension (PTE) System

2024年6月17日
Although PTE has been in the Chinese Patent Law since the 4th Amendment of the law came into effect June 1, 2021, we didn’t really know the exact details of how it operated until the Implementation Regulations and Examination Guidelines (“Implementation Regulations”) were finally released in December 2023. New Rules 77-84 in the Implementation Regulations […]

SPC Upholds $2M RMB Award in China’s First Patent Case on a Biological Deposit

2022年7月4日
On 28 Feb 2022, China’s Supreme People’s Court (SPC) issued its annual “Judgment Digests”, which includes a list of “48 typical cases” highlighting representative SPC decisions in 2021. The Judgment Digests help us understand more about the SPC’s judicial ideology, trial concepts, and adjudication methods in dealing with difficult and sophisticated legal issues as well […]

Beijing Supreme People’s Court Upholds Novo Nordisk Semaglutide Patent in China based on Post-Filing Data

2026年1月23日
On December 31, 2025, The Supreme People's Court upheld the Beijing IP Court's decision, meaning that the semaglutide patent remains valid and will expire on March 20, 2026. Novo Nordisk announced this positive news via a press release on the day the case was decided. The Chinese Ministry of Commerce has also confirmed this decision […]

No % homology? How to craft allowable claim scope around sequences to comply with China’s strict written description requirements

2018年11月23日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]
Top crossarrow-right